Genomics BioSci & Tech. Co., Ltd.

As of June 30, 2026, Genomics BioSci & Tech. Co., Ltd. carries a market capitalization of 1.25B, placing it among publicly traded companies globally. Its enterprise value stands at 1.66B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Genomics BioSci & Tech. Co., Ltd. has 80.00M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.66, and the price-to-book ratio stands at 1.88.

These figures are as of June 30, 2026. The EV/Sales ratio of 5.19 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.66B versus a market cap of 1.25B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Genomics BioSci & Tech. Co., Ltd. maintains a current ratio of 1.43, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 71.79, indicating elevated leverage, while an interest coverage ratio of -4.92 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Genomics BioSci & Tech. Co., Ltd. posted a negative return on equity (ROE) of -1.77, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -0.72, reflecting losses generated across the asset base. The company generates approximately 2.58M in revenue per employee across its workforce of 124.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.05 indicates how many times Genomics BioSci & Tech. Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Genomics BioSci & Tech. Co., Ltd. recorded 613,000.00 in income tax expense. The company reported a pretax loss of -26.54M and -10.39M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

These figures are as of the close on October 22, 2026.

Over the twelve months ended June 30, 2026, Genomics BioSci & Tech. Co., Ltd. generated 320.09M in revenue and converted that into -10.39M in net income, yielding earnings per share of -0.36. EBITDA reached -42.17M, while operating income came in at -84.71M.

As of June 30, 2026, Genomics BioSci & Tech. Co., Ltd. holds 210.46M in cash and equivalents against 537.39M in total debt, resulting in a net debt position of 368.36M. Total book value stands at 665.35M, with working capital of 182.42M providing operational flexibility.

Genomics BioSci & Tech. Co., Ltd. produced -56.45M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -18.35M in capital expenditures, free cash flow totaled -74.80M - equivalent to -1.00 per share.

Over the twelve months ended June 30, 2026, Genomics BioSci & Tech. Co., Ltd. posted a gross margin of 25.88, reflecting its pricing power and cost economics. The operating margin of -26.47 and net profit margin of -3.25 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -6.38: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.95, meaning Genomics BioSci & Tech. Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Genomics BioSci & Tech. Co., Ltd.'s most recent stock split took place on August 8, 2023 with a 50:51 split ratio.

As of June 30, 2026, Genomics BioSci & Tech. Co., Ltd. has an Altman Z-Score of 1.03, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.